193 related articles for article (PubMed ID: 10739698)
1. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum.
Garrett AP; Ng SW; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Apr; 77(1):105-11. PubMed ID: 10739698
[TBL] [Abstract][Full Text] [Related]
2. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum.
Huang LW; Garrett AP; Schorge JO; Muto MG; Bell DA; Welch WR; Berkowitz RS; Mok SC
Am J Clin Pathol; 2000 Jul; 114(1):93-9. PubMed ID: 10884804
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum.
Schorge JO; Miller YB; Qi LJ; Muto MG; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Mar; 76(3):369-72. PubMed ID: 10684712
[TBL] [Abstract][Full Text] [Related]
4. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
5. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum.
Bandera CA; Muto MG; Welch WR; Berkowitz RS; Mok SC
Oncogene; 1998 Jul; 16(26):3455-9. PubMed ID: 9692553
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum.
Muto MG; Welch WR; Mok SC; Bandera CA; Fishbaugh PM; Tsao SW; Lau CC; Goodman HM; Knapp RC; Berkowitz RS
Cancer Res; 1995 Feb; 55(3):490-2. PubMed ID: 7834614
[TBL] [Abstract][Full Text] [Related]
7. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Jamieson S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
9. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
[TBL] [Abstract][Full Text] [Related]
10. K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.
Alvarez AA; Moore WF; Robboy SJ; Bentley RC; Gumbs C; Futreal PA; Berchuck A
Gynecol Oncol; 2001 Feb; 80(2):201-6. PubMed ID: 11161860
[TBL] [Abstract][Full Text] [Related]
11. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
12. Papillary serous carcinoma of the peritoneum coexisting with or after endometrial carcinoma.
Altaras MM; Bernheim J; Zehavi T; Drucker L; Uziel O; Fishman A
Gynecol Oncol; 2002 Feb; 84(2):245-51. PubMed ID: 11812082
[TBL] [Abstract][Full Text] [Related]
13. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis.
Schorge JO; Muto MG; Lee SJ; Huang LW; Welch WR; Bell DA; Keung EZ; Berkowitz RS; Mok SC
Cancer Res; 2000 Mar; 60(5):1361-4. PubMed ID: 10728699
[TBL] [Abstract][Full Text] [Related]
14. Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1.
Bissonnette M; Khare S; von Lintig FC; Wali RK; Nguyen L; Zhang Y; Hart J; Skarosi S; Varki N; Boss GR; Brasitus TA
Cancer Res; 2000 Aug; 60(16):4602-9. PubMed ID: 10969813
[TBL] [Abstract][Full Text] [Related]
15. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis.
Takahashi T; Munakata M; Ohtsuka Y; Nisihara H; Nasuhara Y; Kamachi-Satoh A; Dosaka-Akita H; Homma Y; Kawakami Y
Cancer; 2002 Aug; 95(3):624-33. PubMed ID: 12209756
[TBL] [Abstract][Full Text] [Related]
16. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
[TBL] [Abstract][Full Text] [Related]
17. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma.
Schmitz MJ; Hendricks DT; Farley J; Taylor RR; Geradts J; Rose GS; Birrer MJ
Gynecol Oncol; 2000 Jun; 77(3):439-45. PubMed ID: 10831356
[TBL] [Abstract][Full Text] [Related]
18. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K- ras mutation.
Wang Y; Yamaguchi Y; Watanabe H; Ohtsubo K; Wakabayashi T; Sawabu N
J Gastroenterol; 2002; 37(10):831-9. PubMed ID: 12424567
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS.
Cyniak-Magierska A; Brzeziańska E; Januszkiewicz-Caulier J; Jarzab B; Lewiński A
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):594-9. PubMed ID: 17943694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
